Positive clinical data, competitor focus, and new drug-eluting technologies to drive lower extremity procedures in Europe, according to Millennium Research Group

May 28, 2009—Waltham, Massachusetts—According to Millennium Research Group’s (MRG’s) European Markets for Peripheral Vascular (PV) Devices 2009 report, rapid growth in the number of endovascular procedures that treat lower extremity peripheral artery disease in Europe is being fueled by positive clinical trial results, increased competitor focus, and the release of new drug-eluting devices for these indications. Combined, these factors will drive the markets for lower extremity PV stents and percutaneous transluminal angioplasty (PTA) balloon catheters to reach combined revenues in excess of $180 million by 2013.

The number of endovascular femoropopliteal (fem-pop) procedures performed in Europe is experiencing double-digit year-over-year growth, driven primarily by positive data released from clinical trials such as Cordis’ SIROCCO and Edwards Lifesciences’ RESILIENT. The positive results from these trials have demonstrated both promising patency rates and reduced stent fracture rates, which will continue to bolster physician confidence in fem-pop stenting. Fem-pop PTA procedure volumes in Europe will grow in tandem with fem-pop stenting, which often involves predilation of the lesion or postdilation of the stent using PTA balloon catheters. As a result, most major PV stent manufacturers are now focusing on the fem-pop indication for technology development and marketing.

“Endovascular infrapopliteal procedures, which treat below-the-knee peripheral artery disease, are also growing rapidly,” says Stephanie Labelle, Senior Analyst at MRG. “Although revenues in both the PV stent and PTA balloon catheter markets were relatively small for the infrapopliteal indication in 2008, infrapopliteal procedures will continue to outgrow other PV stenting indications through 2013. In addition, the introduction of drug-eluting stents and balloons indicated for infrapopliteal procedures will generate a considerable amount of physician excitement, which will help to boost market revenues over the years to come.”

MRG’s European Markets for Peripheral Vascular Devices 2009 report provides coverage of key industry competitors, including Abbott Vascular, Boston Scientific, Cook Medical, Cordis, C. R. Bard, Medtronic Vascular, Terumo Medical, W. L. Gore, and many more.